Biocracked
Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
Research

Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?

Dr. Synapse · · 7 min read

Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?

Akwai yanzu gwajin mataki na biyu da aka sarrafa placebo na CBL‑514 a Aesthetic Surgery Journal, kuma marubuta sun rahoto cewa ta cika manyan manufofin farko da na biyu. Wannan ci gaba ne mai mahimmanci idan aka kwatanta da gwaje‑gwajen da suka gabata. Sai dai ƙirar gwajin na da wasu matsaloli da masu karatu masu hankali za su buƙaci su fahimta. Wannan makala tana nazarin ƙirar binciken tare da tambayar wane tambayoyi gwajin zai iya amsa da wane ba zai iya ba. Cikakken teburin sakamakon an ba shi a wani wuri daban.

Wannan bincike ne na kimiyya, ba shawara ta likita ba. CBL‑514 maganin gwaji ne, ba samfurin da aka amince da shi ba, kuma ba kwaya ko tablet ba ne.

Menene CBL‑514 (da abin da ba shi ba)

CBL‑514 wani ƙwayar ƙananan magani ne da kamfanin Caliway Biopharmaceuticals (New Taipei City, Taiwan) ke bincike don rage kitsen jiki. Marubutan gwajin sun bayyana shi a matsayin maganin da ke haifar da mutuwar sel na kitse (apoptosis) da rage kitse a ƙasa da fata a gwaje‑gwajen da ba na mutane ba. A cikin gwajin, an yi allura a ƙasa da fata a cikin ƙugiya.

Abubuwa uku da suka kamata a fahimta:

  • Tasiri a wuri guda. Maganin yana nufin kashe sel na kitse kai tsaye, ba ya ƙara yawan metabolism, ƙona kalori ko rage nauyi gaba ɗaya.
  • Shaidar ƙaƙƙarfan aiki ba ta da yawa a fili. Takardar Phase 2a ta baya ta nuna an hana kinase DYRK1b kuma an ƙara caspase‑3 da Bax/Bcl‑2. Waɗannan ikirari sun dogara ne da rahotannin ciki na Caliway da ba a wallafa ba.
  • Ba a bayyana ainihin sinadarin ba a cikin takardun da aka buga.

Kawai maganin da FDA ta amince da shi don rage kitse a ƙasan wuyar shine ATX‑101 (deoxycholic acid, Kybella). CBL‑514 ba ta da amincewar FDA.

Taswirar shaidu

Mataki na ɗaya: Phase 2a na 2022. Goodman et al. (Aesthetic Surg J 2022; PMC9384315; NCT04698642) gwaji ne mai buɗe ido, da niyyar zaɓen ƙarfi tare da mahalarta 43, kuma ba a samu rukunin placebo ba. Gwajin ya taimaka wajen sanin ƙarfi, amma ba zai iya ware tasirin magani daga tasirin tsammani ko kuskuren auna ba.

Mataki na biyu: Phase 2 na 2025. Gold et al. (Aesthetic Surg J 2025; 45(6):611‑620; PMC12080885; PubMed; DOI: 10.1093/asj/sjaf032; NCT04897412) ya ƙara yin randomisation, placebo na saline da wurare da dama. An gudanar da shi daga Fabrairu 2022 zuwa Maris 2023 a cibiyoyi biyar a Amurka da Australia, tare da rabo 2:1 tsakanin CBL‑514 da placebo. Mujallar ta ba shi darajar shaida 2. Wannan shi ne gwaji na farko da aka sarrafa placebo a wannan rukuni, duk da haka har yanzu yana cikin Phase 2.

Yadda Phase 2 ta gudana

Sharuɗɗan cancanta. Mahalarta su ne manya masu shekaru 18‑64, BMI tsakanin 18.5‑35 kg/m², nauyi aƙalla 50 kg, da kaurin fata a ƙugiya tsakanin 3‑8 cm. Dole su kasance da fata mai kyau a wurin da za a yi magani, tare da lafiya mai kyau na hanta, koda, zuciya da garkuwar jiki, ba tare da cutar da aka sani ba ko cutar kansa.

Tsarin gwaji. An ba mahalarta damar samun allura har zuwa huɗu a tazarar makonni 4, sannan a bibiyar makonni 4 da 8 bayan ƙarshe. Kowanne zama ya ƙunshi allura 25‑50 mL gwargwadon shawarar mai bincike. Kowace allura tana ɗaukar 2.4 mL, ko CBL‑514 da ke 2 mg/cm² (har zuwa 600 mg a kowace magani) ko adadin daidai na saline. Mahalarta su riƙe nauyi ba tare da canji ba; idan nauyi ya ƙaru sama da kilogram 3 za a dakatar da su.

Manufar farko. Manufar ita ce a tantance adadin mahalarta da suka rasa aƙalla mL 150 na kitsen ƙugiya a duka biyun na bibiyar.

Matsakaicin aunawa. An auna girman kitse ta hanyar ultrasound a wurare huɗu, 4‑10 cm daga dama da hagu na ƙugiya. An yi auna sau uku a kowane wuri, kuma masu sonografi da aka horar suka ƙididdige matsakaici. An ƙididdige girman a matsayin kube: yanki na 300 cm² da aka auna a wurare huɗu tare da matsakaicin kauri.

Wannan hanya tana ba da kimantawa, amma ba a auna girma kai tsaye ba. An ɗauka cewa kaurin wurare huɗu ya wakilta dukan yanki na 300 cm². An kuma tattara hotunan 3D (QuantifiCare LifeViz, kusan kusurwoyi takwas).

Tushen ƙididdiga

Adadin mahalarta ya nuna inda ƙirar ke da matsala:

  • An duba mutane 130, an yi rijista 81, an randomize 76 (50 CBL‑514, 26 placebo).
  • Mutane biyar sun janye kafin randomization, ɗaya kuma bayan randomization amma kafin a fara magani, don haka an ba da magani ga 75 (49 CBL‑514, 26 placebo).
  • Kawai 38 cikin 75 ne suka kammala gwajin – wato 49.3 % ba su kammala ba.
  • Dalilan rashin kammala: 6 sun ɓata zuwa bisani, 7 sun janye kansu, 7 sun fuskanci matsalar nauyi, 6 ba za su iya cika jadawalin ba, da 4 da suka samu mummunan abin da ya faru.

Ƙungiyoyin bincike suma suna da bambanci. An fara da 76 a cikin intention‑to‑treat (ITT), yayin da per‑protocol (PP) ya ƙunshi mutane 30 kawai. Maƙasudin biyun na bibiyar a ITT ya ragu: a rukunin CBL‑514, mahalarta 36 ne suka samu a makonni 4, 23 a makonni 8; a placebo 23 da 16. Don haka sakamakon mako 8 an gina shi ne a kan ƙananan adadi na mutanen da aka riga aka zaɓa.

Matsalar sahihanci na ciki: Gaskiya da ainihi

  1. Blind guda ɗaya, ba biyu ba. Mahalarta an goge su ne ta hanyar shingen gani, amma masu bincike, ma’aikatan wurin da mai tallafa (ciki har da mai lura da lafiyar) ba su da blind. Ba a bayyana ko masu sonografi da suka fitar da sakamakon farko sun kasance blind ba. Wannan yana ƙara damuwa game da sakamakon da aka samo daga ultrasound.
  2. Shiga na mai tallafa. Caliway ta shiga ƙira, tattara bayanai, tantancewa da fassara, rubuta takarda da yanke shawarar wallafa. Wannan ba ya kawar da sakamakon, amma yana buƙatar kulawa ta ƙwarai.
  3. Babu daidaiton yawan gwaji. An yi gwaje‑gwaje da dama, lokuta biyu da rukunai biyu a matakin 5 % ba tare da gyara ba. Duk da haka marubuta sun ci gaba da sanar da cikar manufofin farko da na biyu.
  4. Samfurin bincike mai ƙuruciya. Manufar kusan 75 an danganta ta da gwajin Phase 2a maimakon kirga ƙarfi daga babban bayanai.
  5. Rashin halarta. Kimanin rabin mahalarta da aka ba da magani ba su kammala, kuma binciken PP (n = 30) ya dogara ne kan ƙungiyar da aka zaɓa sosai. Ƙididdigar PP galibi tana ba da sakamako mafi kyau saboda tana riƙe waɗanda suka ci gaba da bin dokoki.
  6. Ƙuntatawar gama gari. Rukunin CBL‑514 ya ƙunshi mata 94 % da fararen fata 86 %; rukunin placebo mata 80.8 % da fararen fata 73.1 %. Samfurin ya kuma kasance a cikin mataki ɗaya na BMI da ke da nauyi mai daidaito.
  7. Lokaci gajere. Bibiyar ta ƙare makonni 8 bayan ƙarshe. Gwajin ba zai iya magana kan ɗorewa, aminci na dogon lokaci ko canjin girman kitse a tsawon watanni da dama ba.

Abin da gwajin zai iya amsa da abin da ba zai iya ba

Abubuwan da za a iya amsa da ƙarfi: a cikin ƙungiyar da aka zaɓa wacce ke da nauyi mai daidaito, girman kitsen ƙugiya da ultrasound ya nuna ragin fiye da na saline a kusan watanni biyu, kuma wannan ya faru ba tare da canjin nauyi mai ma'ana ba. Canjin nauyi ya kasance ƙanana a rukuni biyu, don haka ba a samu raguwar nauyi gaba ɗaya ba.

Abubuwan da ba za a iya amsa ba:

  • Ko fa'idodin za su ci gaba bayan makonni 8 bayan magani.
  • Ko sakamakon za su yi aiki a tsakanin al’ummomi daban‑daban.
  • Ko tasirin zai tsaya sosai idan an yi la’akari da yawaitar janyewa, ma’aikatan da ba su da blind, da gwaje‑gwajen da ba a daidaita ba.
  • Yadda CBL‑514 ke kwatanta da cryolipolysis ko liposuction. Marubuta sun kwatanta da binciken cryolipolysis da suka yi amfani da hanyoyin aunawa daban, suna cewa alamar "ya fi girma", sannan suna bayyana sakamako a matsayin "kamar na liposuction". Wannan ra’ayin marubuta ne, ba sakamakon gwaji kai tsaye ba.
  • Sakamakon ingancin fata. Marubuta sun lura da ƙarancin ko babu laxity na fata a hotunan bayan magani, amma wannan ra'ayi ne na gani, ba a ƙayyade a matsayin ma’auni ba.

Har ila yau, wasu mahalarta placebo sun kai matakin mL 150 a mako 4. Wannan na tunatar da mu cewa ƙididdigar girma daga ultrasound na iya ɗaukar hayaniya, kuma dalilin da ya sa ƙirar blind cikakke za ta ƙara ƙarfafa hujja.

Karshe

Takardar 2025 na da muhimmanci: tana da randomisation, placebo, cibiyoyi da yawa kuma a buɗe ake samun dama. Sai dai har yanzu gwaji ne da mai tallafa ya shiga, blind guda ɗaya, na Phase 2 mai yawaitar janyewa da bibiyar gajere. Yana ƙara tallafa wa ƙarin bincike, amma ba ya tabbatar da cewa CBL‑514 magani ne da aka tabbatar ko amintacce don rage kitse.

Manazarta

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

BY DR. SYNAPSE ·

Gwaje‑gwajen CBL‑514 su ne gwaje‑gwajen allura da ke binciken tasirin wannan magani, inda adadin 600 mg ke nufin iyakar adadin da ake amfani da shi a kowanne magani a gwaji, ba adadin da za a ci ba. Wannan makala ta bi takaitaccen binciken Phase 2a don tantance ƙimomi (1.2, 1.6, 2.0 mg/cm² a kan 150 cm², n=43, buɗe‑label) kuma ta fayyace asalin adadin 24.96 % da aka ambata. Sannan ta duba Phase 2 da aka gudanar da placebo, inda aka ci gaba da ƙimar 2.0 mg/cm² amma an ninka yanki zuwa 300 cm² tare da iyaka ta 600 mg. Za ku ga dalilin da yasa adadin mg ba za a iya kwatanta su tsakanin gwaje‑gwajen ba, abin da aka rubuta game da tsaro, da kuma dalilin da ya sanya har yanzu ba a amince da shi ba ko ba da shawara ba.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

BY DR. SYNAPSE ·

CBL‑514 ba a nuna shi a matsayin maganin narkewar ko kona kitse ba. Da'awar da ake yi ita ce yana hanawa kinase DYRK1b aiki sannan ya tilastawa ƙwayoyin kitse shiga apoptosis ta hanyar caspase‑3 da Bax/Bcl‑2. Hujjar wannan zaɓi ta samo asali ne daga rahotannin kamfanin da ba a wallafa ba a takardun Phase 2a da Phase 2, kuma ba a fayyace takamaiman tsarin sinadarin ba. Gwajin Phase 2 na 2025 ya auna girman kitse da ultrasound, hotuna, da aminci, ba tare da ƙarin bayanai kamar biopsi ko caspase ba. Wannan labarin na nuni da bambanci tsakanin tunanin sel da abin da aka auna a ɗan adam, ciki har da yawan mutuwar mahalarta da tsarin single‑blind.

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

BY DR. SYNAPSE ·

CBL‑514 wani allura ne da ake bincike don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. A gwajin mataki na 2 da aka gudanar a 2025 tare da mahalarta 76 da aka raba ta bazuwar, an samu raguwar ƙimar kitse da aka auna ta ultrasound idan aka kwatanta da saline, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Ƙididdigar ta gabatar da ƙirar gwajin, ƙimar 2 mg/cm², cikakkun bayanan tasiri da ƙananan lambobi, da hanyar DYRK1b/caspase da kamfanin ya ba da rahoto. An kuma bayyana iyakokin: ƙirar single‑blind, haɗin gwiwar mai tallafa, kusan 49 % rashin kammalawa, gajeren lokaci na bibiyar, da yawan samfurin mata.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

BY HELIX WARD ·

Binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 bai nufin rage nauyin jiki ba; an duba ko alluran da aka yi a ƙirji za su iya rage aƙalla mililita 150 na kitse a ƙarƙashin fata ta hanyar ultrasound. Bayan makonni 8, kashi 69.6 % (16/23) na masu karɓar CBL‑514 sun cimma wannan ragi, yayin da babu ɗaya a rukunin placebo. Duk da haka, matsakaicin nauyin jiki bai ragu ba (ƙara 0.02 kg) kuma kusan rabi na mahalarta ba su kammala binciken ba. Martani a wurin allura ya kasance gama‑gari, ciki har da ƙura a fata a 71.4 % da zafi mai tsanani a 18.4 %. Wannan shine abin da binciken ya nuna da abin da bai nuna ba.

This page is available in